Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies

The link between type 2 diabetes mellitus (T2DM) and an increased risk of breast cancer (BC) has prompted the exploration of novel therapeutic strategies targeting shared metabolic pathways. This review focuses on the emerging evidence surrounding the potential anti-cancer effects of sodium-glucose...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of pharmacology Jg. 978; S. 176803
Hauptverfasser:	Naeimzadeh, Yasaman, Tajbakhsh, Amir, Nemati, Mahnaz, Fallahi, Jafar
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Netherlands Elsevier B.V 05.09.2024
Schlagworte:	Animals Antineoplastic agents Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Breast neoplasms Breast Neoplasms - drug therapy Clinical Trials as Topic Diabetes mellitus Female Gene mutations Humans Precision medicine SGLT2 inhibitor Sodium-Glucose Transporter 2 Inhibitors - pharmacology Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Breast neoplasms Gene mutations Precision medicine Antineoplastic agents SGLT2 inhibitor Diabetes mellitus
ISSN:	0014-2999, 1879-0712, 1879-0712
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!